株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

オーファンドラッグ (希少疾病用医薬品) の世界市場

Orphan Drugs

発行 Global Industry Analysts, Inc. 商品コード 285000
出版日 ページ情報 英文 436 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.35円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
オーファンドラッグ (希少疾病用医薬品) の世界市場 Orphan Drugs
出版日: 2018年01月01日 ページ情報: 英文 436 Pages
概要

当レポートでは、世界のオーファンドラッグ市場について調査し、市場の概要と競合動向、製品概要、地域別の動向、および市場に参入する企業のプロファイルなどをまとめています。

第1章 イントロダクション、調査方法、製品定義

第2章 エグゼクティブサマリー

  • 業界概要
    • 序論
    • メーカーによるオーファンドラッグ導入増加
    • 1983年のオーファンドラッグ法が業界のキックスタート
    • 世界の主なオーファンドラッグ法規制
    • オーファンドラッグ市場は急速に成長
    • 米国、カナダ、EUにおける奇病対応組織
    • 米国、EU、日本におけるオーファンドラッグに対する取り組み
    • 市場の課題
    • オーファンドラッグ研究を実施する際の障壁
    • 競合
    • オーファンドラッグは医薬品パイプラインにおいて強固な状態を維持
    • パイプラインにある重要なオーファンドラッグ
  • 成長促進因子
    • 法規制インセンティブ
    • アンメットニーズの増大
    • 稀な癌の発症率上昇
    • 癌のためのオーファンドラッグ
    • 腎細胞癌の発症率上昇
    • 高齢化
    • 症状が出る前の検査
    • アジアの認知度向上
  • 市場動向
  • オーファンドラッグに対するFDAの認可
  • オーファンドラッグ指定
  • 法規制シナリオ
  • 製品概要
    • オーファンドラッグ:序論
    • オーファンドラッグの研究進捗
    • オーファンドラッグの定義 他
  • 製品認可/上市
  • 近年の業界活動
  • 主要企業
    • AbbVie, Inc.
    • Actelion Pharmaceuticals Ltd.
    • Alexion Pharmaceuticals, Inc.
    • Amgen, Inc.
    • AstraZeneca Plc.
    • Bayer AG
    • Biogen Inc.
    • BioMarin Pharmaceutical Inc.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Celgene Corp.
    • CEL-SCI Corporation
    • Concordia International Corp.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Merck Serono International S.A.
    • Novartis AG
    • Pfizer, Inc.
    • Recordati S.p.A.
    • Orphan Europe
    • Shire Plc.
    • Sanofi SA
    • Genzyme Corp.
    • Vertex Pharmaceuticals
  • 世界市場見通し

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
  • その他の諸国
目次
Product Code: MCP-7443

This report analyzes the worldwide markets for Orphan Drugs in US$ Million by the following Product Segments: Biologics, and Non-Biologics. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 140 companies including many key and niche players such as -

AbbVie, Inc.
Actelion Pharmaceuticals Ltd.
Alexion Pharmaceuticals, Inc.
Amgen, Inc.
AstraZeneca Plc
Bayer AG

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • A Prelude
    • Table 1: List of Orphan Drug Designation Criteria in Various Countries
    • Table 2: Select Orphan Diseases and their Prevalence (includes corresponding Graph/Chart)
  • Increasing Adoption of Orphan Drugs by Manufacturers
  • The 1983 Orphan Drugs Act (ODA) Kickstarts the Industry
  • Major Orphan Drugs Legislations Worldwide
  • Orphan Drugs Market on a Rapid Growth Trajectory
    • Table 3: Orphan Drug Designations: 2010 to 2016 (includes corresponding Graph/Chart)
  • Select Major Organizations Dealing with Rare Diseases in the US, Canada, and EU
  • Incentives for Orphan Drug Designation Products in the US, EU, and Japan
  • Market Challenges
  • Obstacles for Conducting Orphan Drug Research
  • Competition
    • Table 4: Global Orphan Drugs Market by Leading Brand: Percentage Market Share for 2016 (includes corresponding Graph/Chart)
  • Orphan Drugs Remain Strong in the Pharmaceutical Pipeline
  • Important Orphan Drugs in Pipeline

2. GROWTH DRIVERS

  • Regulatory Incentives - A Push in the Right Direction
  • Growing Unmet Medical Needs - Fulfilling the Gap
  • Rising Incidence of Rare Forms of Cancer - Opportunities Galore
    • Table 5: Growing Burden of Cancer Worldwide - Number of New Cancer Cases and Cancer-Related Deaths for the Year 2012 and 2030 (includes corresponding Graph/Chart)
    • Table 6: Common Cause of Cancer Deaths Worldwide - Number of Deaths due to Select Types of Cancer for 2015 (includes corresponding Graph/Chart)
    • Table 7: New Cancer Cases in the World by Affected Site: 2012 (in Thousands) (includes corresponding Graph/Chart)
  • Select Orphan Drugs for Cancer
  • Rise in Incidence of Renal Cell Carcinoma
  • Unmet Needs in AML
  • Aging Population Offers Growth Potential
    • Table 8: Global Population Statistics for the 65+ Age Group (2016) (includes corresponding Graph/Chart)
  • Pre-Symptomatic Screening to Expand Market Base
  • Asia's Rising Awareness and Growing Population to Drive Sales

3. SELECT MARKET TRENDS

  • Drug Repurposing Provides Therapies for Rare Diseases
    • Table 9: Major Blockbuster Pharma Drugs Having Orphan Designation (includes corresponding Graph/Chart)
  • The Trend of Old Drugs Re-Surfacing as Orphan Drugs Surges
  • Interest of Major Pharmaceutical Firms Signal a Shift in Commercial Dynamics
  • Mergers and Acquisitions Drive Market Growth
  • Select Mergers & Acquisitions for Orphan Drugs as of the Year 2016
  • Growing Scrutiny over Skyrocketing Prices
  • Orphan Drugs with High Prices: 2016
    • Table 10: Few Orphan Drug Novel Therapies with Exorbitant Prices (includes corresponding Graph/Chart)
  • Medical Advancements Foster Growth
  • Full Reimbursements Critical for Spurring Uptake of High-Priced Orphan Drugs
    • Table 11: Orphan Drug Prices (includes corresponding Graph/Chart)
    • Table 12: Orphan Drugs Vs Non-Orphan Drugs Average Cost (in Dollars) per Patient per Year 2012-2016 (includes corresponding Graph/Chart)
    • Table 13: Orphan Drugs Vs Non-Orphan Drugs Median Cost (in Dollars) per Patient per Year 2012-2016 (includes corresponding Graph/Chart)
  • Regulators to Scrutinize Exorbitant Pricing of Ultra-Orphan Drugs
    • Table 14: US FDA Approval of Ultra-Orphan Non-Cancer Drugs
  • Strong Market Potential for Ultra-Orphan Drugs for Amyloid Light-chain Amyloidosis
  • Increasing Patient Engagement - The PAG Trend
  • Gene Therapy and Bioprocessing Preferred over Chronic Therapies
  • Companies Developing Gene Therapies
  • International Collaboration - The Way Forward
  • CNS Therapeutics to Gain Focus in the Orphan Drugs Market
    • Table 15: CNS Orphan Drug Designations by Therapeutic Area: 2016 (includes corresponding Graph/Chart)
  • Manufacturers Target Orphan Indications to Curtail Competition in Broader Indications
  • Manufacturers Use Orphan Disease to Target Larger Therapeutic Indications
  • Treating Autism - The Next Big Thing?
  • Sequencing Technology - The New Research Tool for Orphan Drugs
  • Innovations in Biotechnology - A Boon for Orphan Drug Research
  • Aging Gene Linked to Myeloma
  • Antibody with Potential to Treat Multiple Myeloma
  • Potential Treatment for Cystic Fibrosis Patients Infected with Mycobacterium abscessus
  • Genetic Variants to Improve Treatment of Non-small Cell Lung Cancer

4. ORPHAN DRUG FDA APPROVALS

  • FDA Approved Orphan Drugs (as of July 2017)
  • FDA Approved Orphan Drugs (2016)
  • FDA Approved Orphan Drugs (2015)
  • FDA-Approved Orphan Drugs (2015)

5. ORPHAN DRUG DESIGNATIONS

  • Select Orphan drug designation: 2017 (total 433 as of november 17, 2017)
  • Select Orphan drug designations: 2016 (total 333)

6. REGULATORY SCENARIO

  • The Need for Regulation
  • US - The Orphan Drug Act of 1983
  • The Amended Pharmaceutical Law 1993 (Japan)
  • The Australian Orphan Drugs Program - 1997
  • The European Regulation on Orphan Medicinal Products - 1999

7. PRODUCT OVERVIEW

  • Orphan Drugs - A Prologue
    • Table 16: Number of Incidences Determining the Orphan Status of a Disease by Region (includes corresponding Graph/Chart)
    • Table 17: Definitions of Orphan Diseases in Different Countries
  • Orphan Drugs Research Progress
  • Select Orphan Disease Definitions
  • Glioblastoma Multiforme
  • Cystic Fibrosis
  • Lyosomal Storage Disorders
  • Fabry Disease
  • Gaucher's Disease
  • Pompe Disease
  • Huntington's Disease
  • Lymphoma
  • Multiple Myeloma
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Chronic Myelogenous Leukemia (CML)
  • Cushing's syndrome
  • Short Bowel Syndrome (SBS)
  • Duchenne's Muscular Dystrophy (DMD)
  • Hemophilia
  • Homozygous Familial Hypercholesterolemia (hoFH)
  • Idiopathic Pulmonary Fibrosis (IPF)
  • Metastatic Melanoma
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Ph+ALL
  • Ultra-Orphan Drugs
    • Table 18: Select Ultra-Orphan Diseases with Global Registered Cases but No Available Prevalence Data (includes corresponding Graph/Chart)
  • Orphan Drug Categorization
  • Designation of Orphan Status
  • Personalized Medicine and Orphan Drugs
  • Regulatory Differences between the US and EU

8. SELECT PRODUCT APPROVALS/LAUNCHES

  • TiGenix Receives FDA Orphan Drug Designation for Cx601
  • FDA Grants Orphan Drug Designation for Emerald Health Pharmaceuticals lead molecule, EHP-101, to Treat Systemic Scleroderma
  • RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON
  • FDA Awards Orphan Drug Status to uniQure's Potential Huntington's Therapy
  • Boston Biomedical Receives Orphan Drug Designation from FDA for DSP-7888
  • Amicus Receives FDA Orphan Drug Status for ATB200/AT2221
  • Roche's Actemra/RoActemra (tocilizumab) Receives FDA Approval to Treat CAR T Cell-induced Cytokine Release Syndrome
  • AGTC Receives FDA Orphan Drug Designation for Gene Therapy Product Candidate
  • Polyneuron' PN-1007 Receives Orphan Drug Status from European Medicines Agency
  • FDA Grants Orphan Drug Designation to Versantis VS-01
  • Innovate Biopharmaceuticals Applies for FDA's Orphan Drug Designation for INN-108
  • FDA Grants Orphan Drug Status for Biohaven's BHV-5000
  • Mithra Receives Orphan Drug Designation for E4
  • AstraZeneca Receives Orphan Designation from EMA for inebilizumab
  • Boehringer Ingelheim gets FDA Orphan Drug Status for BI 836858
  • Biostage gets FDA Orphan Drug Designation for Cellspan Esophageal Implant
  • AbbVie Obtains FDA Orphan Drug Designation for Risankizumab
  • AbbVie gets FDA Orphan Drug Designation for Veliparib
  • TiGenix Receives Orphan Drug Designation for Cx601
  • Boehringer Ingelheim gets FDA Orphan Drug Designation for nintedanib
  • AstraZeneca Receives FDA Orphan Drug Designation for Selumetinib
  • Amarantus gets FDA Orphan Drug Designation for Eltoprazine
  • AM-Pharma Secures FDA & EMA Orphan Drug Designation
  • AstraZeneca's Tremelimumab Receives FDA Orphan Drug Designation
  • BioArbitrage chooses to focus on the Dynamic Rare Disease Sector
  • Acer Therapeutics ACER-002 Receives FDA Orphan Drug Designation

9. RECENT INDUSTRY ACTIVITY

  • Ergomed Plc Plans to Acquire PSR Group BV
  • UDG Healthcare Acquires Cambridge BioMarketing
  • Horizon Pharma Acquires River Vision Development Corp. and Teprotumumab
  • Sun Pharma's Indirect arm Taro Announces Acquisition of Thallion Pharmaceuticals
  • Johnson & Johnson Plans to Acquire Actelion
  • Escend Offers Opportunity to Acquire or License ES-3000
  • Horizon Pharma Agrees to Take Over Raptor Pharmaceutical
  • Savara Acquires Serendex Pharmaceuticals
  • InSite Vision Inks definitive Agreement with QLT Inc
  • Roche Plans to Take over Trophos

10. FOCUS ON SELECT PLAYERS

  • AbbVie, Inc. (USA)
  • Actelion Pharmaceuticals Ltd. (Switzerland)
  • Alexion Pharmaceuticals, Inc. (USA)
  • Amgen, Inc. (USA)
  • AstraZeneca Plc. (UK)
  • Bayer AG (Germany)
  • Biogen Inc. (USA)
  • BioMarin Pharmaceutical Inc. (USA)
  • Boehringer Ingelheim GmbH (Germany)
  • Bristol-Myers Squibb Company (USA)
  • Celgene Corp. (USA)
  • CEL-SCI Corporation (USA)
  • Concordia International Corp. (Canada)
  • Eli Lilly and Company (USA)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Johnson & Johnson (USA)
  • Merck & Co., Inc. (USA)
  • Merck Serono International S.A. (Germany)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (USA)
  • Recordati S.p.A. (Italy)
  • Orphan Europe (France)
  • Shire Plc. (Ireland)
  • Sanofi SA (France)
  • Genzyme Corp. (USA)
  • Vertex Pharmaceuticals (USA)

11. GLOBAL MARKET PERSPECTIVE

    • Table 19: World Recent Past, Current & Future Analysis for Orphan Drugs by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 20: World Historic Review for Orphan Drugs by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 21: World 14-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
  • Analysis by Product Segment
    • Table 22: World Recent Past, Current & Future Analysis for Orphan Biologic Drugs by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 23: World Historic Review for Orphan Biologic Drugs by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed With Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 24: World 14-Year Perspective for Orphan Biologic Drugs by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    • Table 25: World Recent Past, Current & Future Analysis for Orphan Non-Biologic Drugs by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 26: World Historic Review for Orphan Non-Biologic Drugs by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 27: World 14-Year Perspective for Orphan Non-Biologic Drugs by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Current and Future Analysis
    • Table 28: Prevalence and Prices of Select Orphan Drugs in the US (includes corresponding Graph/Chart)
    • Table 29: Leading Drugs in the US Orphan Drugs Market: Market Share of Sales in Percentage for the year 2016 (includes corresponding Graph/Chart)
    • Orphan Drug Act - A Milestone Legislation
    • US Leads the Orphan Drug Approval Landscape
    • Table 30: Number of Orphan Drug Approvals and Designations: 1983 to 2016 (includes corresponding Graph/Chart)
    • Table 31: Number of FDA Approved Orphan Drugs by Type: 2013-2016 (includes corresponding Graph/Chart)
    • Regulatory Overview
      • US Orphan Drugs Policy - A Snapshot
      • Orphan Products Grants Program
      • Humanitarian Use Device (HUD) Program
      • Select CDRH Approved Devices for Rare Diseases
    • Medicare Reimbursement for Orphan Drugs
      • Reimbursement for Orphan Drugs Not on Single-Indication List
      • Orphan Drug Modernization Plan
    • Priority Review of Orphan Drugs Becomes Popular
      • FDA Review Time Reduced for Priority Review Designation
    • Table 32: Majority of Orphan Drugs Undergo Priority Review: 2015 (includes corresponding Graph/Chart)
    • Product Approvals
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 33: The US Recent Past, Current & Future Analysis for Orphan Drugs by Product Segment - Biologic Drugs and Non-Biologic Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 34: The US Historic Review for Orphan Drugs by Product Segment - Biologic Drugs and Non-Biologic Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 35: The US 14-Year Perspective for Orphan Drugs by Product Segment - Percentage Breakdown of Value Sales for Biologic Drugs and Non-Biologic Drugs Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

2. JAPAN

  • A. Market Analysis
    • Current and Future Analysis
    • Regulatory Overview
    • Table 36: Comparison of Japanese Orphan Drug Designation System with the US and Europe
      • New Orphan Drugs in Japan: 2015-2017
    • Table 37: Japanese Orphan Drugs Designation by Therapeutic Area: 2016 (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 38: Japanese Recent Past, Current & Future Analysis for Orphan Drugs by Product Segment - Biologic Drugs and Non-Biologic Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 39: Japanese Historic Review for Orphan Drugs by Product Segment - Biologic Drugs and Non-Biologic Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 40: Japanese 14-Year Perspective for Orphan Drugs by Product Segment - Percentage Breakdown of Value Sales for Biologic Drugs and Non-Biologic Drugs Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

3. EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Table 41: Leading Drugs in the European Orphan Drugs Market: Market Share of Sales in Percentage for the year 2016 (includes corresponding Graph/Chart)
    • Table 42: European Orphan Medicinal Product Designations since 2008 (includes corresponding Graph/Chart)
    • Table 43: EU Orphan Designation by Therapeutic Indications: As of 2015 (includes corresponding Graph/Chart)
      • Orphan Drug Marketing Authorizations in Europe: As of Sept 2017
      • Orphan Drug Marketing Authorizations in Europe: 2016
    • The European Regulation on Orphan Medicinal Products - 1999
      • EU Orphan Drug Regulation Overview
      • Orphan Drugs Policies Summary in Select European Countries
    • Product Approvals
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Table 44: European Recent Past, Current & Future Analysis for Orphan Drugs by Product Segment - Biologic Drugs and Non-Biologic Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 45: European Historic Review for Orphan Drugs by Product Segment - Biologic Drugs and Non-Biologic Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 46: European 14-Year Perspective for Orphan Drugs by Product Segment - Percentage Breakdown of Value Sales for Biologic Drugs and Non-Biologic Drugs Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4. REST OF WORLD

  • A. Market Analysis
    • Current and Future Analysis
    • Asia's Rising Awareness and Growing Population to Drive Sales
      • Orphan Drugs Legislation in Select Asia-Pacific Countries: 2014
    • Regulatory Scenario in Select Countries
      • Australia
      • China
      • Orphan Drugs Market Set to Grow in China
      • The Chinese Food and Drug Administration (CFDA)
      • India
      • Lack of Awareness Limits the Growth of Orphan Drug Development
      • Malaysia
      • Malaysia to Develop a National Framework for the Management of Rare Diseases
      • Thailand
      • Singapore
      • South Africa
      • South Korea
      • Taiwan
    • Strategic Corporate Development
    • Select Key Player
  • B. Market Analytics
    • Table 47: Rest of World Recent Past, Current & Future Analysis for Orphan Drugs by Product Segment - Biologic Drugs and Non-Biologic Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 48: Rest of World Historic Review for Orphan Drugs by Product Segment - Biologic Drugs and Non-Biologic Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 49: Rest of World 14-Year Perspective for Orphan Drugs by Product Segment - Percentage Breakdown of Value Sales for Biologic Drugs and Non-Biologic Drugs Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top